BioMedNewsBreaks

MondayJul 27, 2026 2:17 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds on End-to-End Platform Connecting Telemedicine, Pharmacy and Fulfillment

Earth Science Tech (OTC: ETST) recently announced fiscal year 2026 results for the year ended March 31, 2026, highlighting growth across key financial metrics as it continues to operate its diversified holdings model spanning healthcare, pharmaceuticals, telemedicine, real estate and consumer businesses. Revenue increased 8% to $35.7 million, gross profit rose 5% to $25.5 million, net income grew 11% to $3.6 million, and total assets increased 27% to $9 million. CEO Giorgio R. Saumat attributed the results to ETST’s efforts to fully integrate the patient experience across telemedicine to pharmacy to fulfillment. To view the full article, visit https://ibn.fm/mY8eX About Earth Science Tech…

Continue Reading

MondayJul 27, 2026 11:46 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures 

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members. The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital…

Continue Reading

MondayJul 27, 2026 11:31 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an "AND-gate" approach intended to improve precision in treating solid tumors. Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize…

Continue Reading

ThursdayJul 23, 2026 9:30 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the…

Continue Reading

WednesdayJul 22, 2026 11:57 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) together with Sapu Nano, announced publication of a peer-reviewed study in Biomedicines detailing the preclinical data supporting Sapu003, its intravenous Deciparticle(TM) formulation of everolimus. The publication outlines the program's absorption, distribution, metabolism, excretion ("ADME"), pharmacokinetics, tissue distribution, GLP toxicology and cGMP manufacturing data, supporting the ongoing Phase 1 clinical evaluation of Sapu003 in patients with advanced solid tumors. According to the company, the formulation is designed to overcome pharmacokinetic limitations associated with oral everolimus while preserving the drug's metabolic profile. The published findings also describe reduced gastrointestinal drug exposure compared with oral everolimus, no treatment-related gastric pathology in repeat-dose GLP toxicology studies and…

Continue Reading

TuesdayJul 21, 2026 1:08 pm

BioMedNewsBreaks — VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement 

VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds through a private placement of 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants priced at a combined $0.85 per share. The warrants, which are exercisable following shareholder approval and expire five years after their initial exercise date, carry an exercise price of $0.85 per share. The company also agreed, subject to shareholder approval, to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share. The offering is…

Continue Reading

MondayJul 20, 2026 10:41 am

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology 

Regentis Biomaterials (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC(R), the company's regenerative treatment for articular cartilage injuries. Regentis said the allowance expands its global intellectual property portfolio as it advances GelrinC commercialization in Europe, continues enrollment in its pivotal U.S. clinical trial and evaluates expansion into additional international markets. The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable liquid formulations. According to the company, the technology improves manufacturing efficiency, increases production yield, simplifies manufacturing and enhances scalability for commercial…

Continue Reading

MondayJul 20, 2026 9:30 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development. VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets…

Continue Reading

FridayJul 17, 2026 3:23 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Voice-Based AI Technology for Real-Time Impairment Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is developing an AI-powered voice analysis platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional breath, saliva, urine and laboratory-based testing. Trained on more than 50 million data points and analyzing over 140 acoustic markers, the technology aims to deliver real-time impairment assessments through Edge AI kiosks, with initial field testing planned in 2026 and an initial commercial focus on South American mining operations, where large-scale workforce screening presents significant safety…

Continue Reading

ThursdayJul 16, 2026 2:56 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at the Intersection of AI and Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is leveraging artificial intelligence, epigenetics, and genetics to improve the early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests, addressing a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050. The company’s proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. Cardio Diagnostics has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes,…

Continue Reading